The following information is disclosed in accordance with Rule 26 of the AIM Rules for Companies.
Last Updated 11 February 2020
Mereo is an innovative leader in the specialty biopharma sector with a focus on acquiring, developing and optimising the value of innovative medicines designed to address significant unmet medical needs in rare and specialty disease areas, and improve patient quality of life.
Please click on the link for the names and brief biographical details of the details of the directors together with a description of their responsibilities
Please click on the link below for information on the Audit and Risk Committee, Remuneration Committee and Nomination Committee, together with the membership of those committees.
Mereo Biopharma Group plc ("Mereo") is incorporated in England and Wales and the UK is the Company's main country of operation.
Please click on the link for information of the Company’s Nominated Adviser and other key advisers, including contact details.
Please click on the link to access the notifications made by the Company in the past 12 months.
Please click on the link for access to the Company’s annual and interim reports.
Mereo BioPharma Group plc is listed on the AIM market of the London Stock Exchange (LSE). The Company's American Depository Shares (ADSs) are listed on the Nasdaq Global Market.
Please click on the link for details of the number of securities in issue, the number of securities held as treasury shares and, insofar as the Company is aware, the percentage of securities that is not in public hands together with the identity and percentage holdings of significant shareholders.
There are no restrictions on the transfer of securities.
The Company is subject to the UK City Code on Takeovers and Mergers (the City Code) issued and administered by the Panel on Takeovers and Mergers (the Takeover Panel).